Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation

Chih-Hsien Cheng; Hao-Chien Hung; Jin-Chiao Lee; Yu-Chao Wang; Tsung-Han Wu; Chen-Fang Lee; Ting-Jung Wu; Hong-Shiue Chou; Kun-Ming Chan; Wei-Chen Lee

doi:10.12659/AOT.938731

21 April 2023 : Original article

Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation

Chih-Hsien Cheng^1ABCDE*, Hao-Chien Hung^1BC, Jin-Chiao Lee^1BC, Yu-Chao Wang^1CD, Tsung-Han Wu^1CD, Chen-Fang Lee^1ABC, Ting-Jung Wu^1BC, Hong-Shiue Chou^1BC, Kun-Ming Chan

^1BC, Wei-Chen Lee^1ABCD

DOI: 10.12659/AOT.938731

Ann Transplant 2023; 28:e938731

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 4 Renal function change during therapy with TDF and TAF after stratifying by stages of chronic kidney disease(A) Median and IQR eGFR and (B) eGFR percent change from baseline at weeks 12, 24, 36 and 48 during TDF and TAF therapy. (C) eGFR percent change of stage 3b and 4 patients during TAF. n.s. – not significant, *** p<0.001 (one-way ANOVA).

Back to the Article

Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation

Your Privacy